Informatics
Grundium has manufactured its 1000th microscope scanner
On March 24th, 2021 Grundium manufactured its 1000th microscope scanner. Grundium has fast become a serious player in digital pathology, providing a small footprint, high-precision and easy to use imaging component fitting any workflow at a...
Validation of PD-L1 AI model launches in six labs across the Nether...
- Artificial Intelligence
- Business
- Case of the Month
- Clinical Laboratories
- Cloud Computing
- Data Management
- Device Manufacturers
- Digital Pathology Interview
- Digital Pathology News
- Image Analysis
- Informatics
- International
- Laboratory Informatics
- Marketing
- New Digital Imaging Technologies
- Pathology News
- Vendor products
Labs in the Netherlands are joining together to launch an AI model validation study for PD-L1 scoring with a goal of multi-source domain adaptation. Introduction Programmed death-ligand 1 (PDL1) is a protein that, when attached to T...
New Developments in Leukemia Apr 20, 2021 9 am PT / Noon ET Host: Derek Lyle, MD; Medical Director, NeoGenomics Speaker: Daniel A. Arber, MD; Chair of Pathology and Donald West and Mary Elizabeth King Professor of Pathology, The...
Tomorrow: DeePathology™ STUDIO 2021
March 16, 2021 at 17:00 CET Jacob Gildenblat, DeePathology's CTO, will present the new features of the DeePathology STUDIO including: Enhanced cell detection mode for quickly creating algorithms in complex scenarios Powerful...
Join us for the NeoGenomics Virtual Molecular Tumor Boards
NeoGenomics would like to invite you to our Molecular Tumor Boards. During each meeting, multidisciplinary teams will have a live discussion consulting on multiple cases with expert oncologists and discuss optimal treatment plans. Previous...
How Motic Uses Digital Pathology to Combat Cervical Cancer
How Motic Uses Digital Pathology to Combat Cervical Cancer Cervical cancer is considered a leading cause of cancer-related deaths among women worldwide. Let that sink in — a cancer that’s largely preventable by the HPV vaccine and, at...
































